Ziva D Cooper

Title(s)Professor-in-Residence, Psychiatry and Biobehavioral Sciences
SchoolMedicine
vCardDownload vCard
    Other Positions
    Title(s)Professor-in-Residence, Anesthesiology


    Collapse Biography 
    Collapse Education and Training
    University of Michigan, Ann ArborPhD2007Biopsychology

    Collapse Overview 
    Collapse Overview
    Dr. Ziva Cooper, Ph.D. is the Director of the UCLA Center for Cannabis and Cannabinoids in the Jane and Terry Semel Institute for Neuroscience and Human Behavior and Professor in the UCLA Departments of Psychiatry and Biobehavioral Sciences and Anesthesiology. Her research involves understanding variables that influence both the therapeutic potential and adverse effects of cannabis and cannabinoids, the chemicals in the cannabis plant. Her current projects funded by the NIH and California State include understanding the potential for cannabis constituents to reduce reliance on opioids, differences between men and women in their response to the pain-relieving effects of cannabis, effects of cannabis as a function of age, and therapeutic effects of cannabinoids in patient populations. Dr. Cooper served on the National Academies of Sciences Committee on the Health Effects of Cannabis that recently published a comprehensive report of the health effects of cannabis and cannabinoids. She is the President-elect of the International Cannabinoid Research Society, a past Board Director for the College on Problems of Drug Dependence, an Associate Editor of The American Journal of Drug and Alcohol Abuse and Neuropsychopharmacology, and is on several Editorial Boards of journals including Cannabis and Cannabinoid Research.

    Collapse Research 
    Collapse Research Activities and Funding
    Age-and sex-dependent pharmacodynamics and pharmacokinetics of oral and smoked delta-9-THC
    NIH/NIDA R01DA057252Jul 1, 2022 - Jun 30, 2027
    Role: Principal Investigator
    Assessing the Feasibility and Consequences of Implementing a Cannabis Potency Tax in California
    California Department of Cannabis Control 65387Sep 1, 2021 - Aug 31, 2023
    Role: Principal Investigator
    Assessing Oral Fluid Testing Device Ability to Detect Recent Drug Use
    California Highway Patrol 20C066000Sep 1, 2020 - Aug 31, 2023
    Role: Principal Investigator
    Analgesic and subjective effects of terpenes administered alone and in combination with THC: Potential THC- and opioid-sparing effects of myrcene and ß-caryophyllene
    NIH R01AT010762Feb 15, 2020 - Jan 31, 2025
    Role: Principal Investigator
    Therapeutic Response of Cannabidiol in Rheumatoid Arthritis
    Center for Medicinal Cannabis Research P64-01-003Oct 1, 2019 - Sep 30, 2023
    Role: Co-Principal Investigator
    Sex-dependent effects of cannabis: Assessing abuse-related and pharmacokinetic differences between men and women
    NIH R01DA047296Sep 15, 2019 - Jun 30, 2024
    Role: Principal Investigator
    Impact of vaporized cannabis with varying cannabidiol and THC ratios on opioid abuse-liability and analgesia
    NIH R21DA046614Aug 1, 2018 - Jul 31, 2021
    Role: Co-Principal Investigator
    Preclinical Synthetic Cannabinoid Vapor Inhalation: Acute and Chronic Effects
    NIH R01DA039123May 1, 2015 - Apr 30, 2019
    Role: Co-Principal Investigator
    Synthesis of Smokable Synthetic Cannabinoids ('Spice') for Human Study
    NIH R21DA036809Aug 1, 2014 - Jul 31, 2017
    Role: Principal Investigator
    Behavioral and Physiological Effects of Marijuana on Smoked Cocaine
    NIH K01DA027755Apr 1, 2010 - Mar 31, 2016
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. The role of sex in daily levels of high-risk alcohol and cannabis co-use. Drug Alcohol Depend Rep. 2023 Dec; 9:100203. McManus K, Venegas A, Henry B, Cooper ZD, Grodin EN, Ray LA. PMID: 38035048; PMCID: PMC10681919.
      View in: PubMed   Mentions:
    2. Assessing evidence supporting cannabis harm reduction practices for adolescents at clinical high-risk for psychosis: a review and clinical implementation tool. Psychol Med. 2024 Jan; 54(2):245-255. Kapler S, Adery L, Hoftman GD, Amir CM, Grigoryan V, Cooper ZD, Bearden CE. PMID: 37882050.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    3. Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer. Cancer Res Commun. 2023 09 22; 3(9):1917-1926. Brasky TM, Newton AM, Conroy S, Adib A, Adley NC, Strassels SA, Hays JL, Cooper ZD, Wagener TL, Stevens E, Plascak JJ, Krok-Schoen JL. PMID: 37772996; PMCID: PMC10515742.
      View in: PubMed   Mentions: 3  Translation:HumansAnimals
    4. Associations of U.S. state-level COVID-19 policies intensity with cannabis sharing behaviors in 2020. Res Sq. 2023 Aug 02. Assaf RD, Hamad R, Javanbakht M, Arah OA, Shoptaw SJ, Cooper ZD, Gorbach PM. PMID: 37577641; PMCID: PMC10418562.
      View in: PubMed   Mentions:
    5. Kratom Alkaloids, Cannabinoids, and Chronic Pain: Basis of Potential Utility and Role in Therapy. Cannabis Cannabinoid Res. 2023 Jul 19. Farkas DJ, Cooper ZD, Heydari LN, Hughes AC, Rawls SM, Ward SJ. PMID: 37466474.
      View in: PubMed   Mentions: 1     Fields:    
    6. Sex differences in the subjective and reinforcing effects of smoked cannabis. Addict Biol. 2023 07; 28(7):e13301. Lake S, Haney M, Cooper ZD. PMID: 37369126; PMCID: PMC10300354.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    7. Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials. Nat Med. 2023 Jun; 29(6):1487-1499. Haney M, Vallée M, Fabre S, Collins Reed S, Zanese M, Campistron G, Arout CA, Foltin RW, Cooper ZD, Kearney-Ramos T, Metna M, Justinova Z, Schindler C, Hebert-Chatelain E, Bellocchio L, Cathala A, Bari A, Serrat R, Finlay DB, Caraci F, Redon B, Martín-García E, Busquets-Garcia A, Matias I, Levin FR, Felpin FX, Simon N, Cota D, Spampinato U, Maldonado R, Shaham Y, Glass M, Thomsen LL, Mengel H, Marsicano G, Monlezun S, Revest JM, Piazza PV. PMID: 37291212; PMCID: PMC10287566.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCTClinical Trials
    8. Cannabis Use and Sharing Practices Among Sexual Minority and Heterosexual Individuals During the COVID-19 Pandemic. LGBT Health. 2023 10; 10(7):514-525. Assaf RD, Javanbakht M, Gorbach PM, Cooper ZD. PMID: 37252794; PMCID: PMC10552144.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsPHPublic Health
    9. Adolescent Cannabis Misuse Scale: Longitudinal Associations with Substance Use, Mental Health, and Social Determinants of Health in Early Adulthood. Subst Use Misuse. 2023; 58(9):1080-1089. Meza BPL, Dudovitz RN, Cooper ZD, Tucker JS, Wong MD. PMID: 37158563; PMCID: PMC10286726.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    10. Changes in Immune-Related Biomarkers and Endocannabinoids as a Function of Frequency of Cannabis Use in People Living With and Without HIV. Cannabis Cannabinoid Res. 2023 Apr 20. Murray CH, Javanbakht M, Cho GD, Gorbach PM, Fulcher JA, Cooper ZD. PMID: 37093248.
      View in: PubMed   Mentions: 1     Fields:    
    11. Shifts in medical cannabis use in Canada during the COVID-19 pandemic. Health Promot Chronic Dis Prev Can. 2023 Mar; 43(3):119-129. Lake S, Cooper ZD, Ong K, Lucas P. PMID: 36924465; PMCID: PMC10101038.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsPHPublic Health
    12. Puff, Puff, Don't Pass: harm reduction for cannabis use during a viral respiratory pandemic. Harm Reduct J. 2023 02 25; 20(1):23. Assaf RD, Javanbakht M, Gorbach PM, Arah OA, Shoptaw SJ, Cooper ZD. PMID: 36829150; PMCID: PMC9957690.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsPHPublic Health
    13. Controlled human drug administration studies are necessary to define the THC-sparing effects of CBD and other cannabis constituents. Neuropsychopharmacology. 2023 05; 48(6):850-851. Pabon E, Cooper ZD. PMID: 36725865; PMCID: PMC10156753.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    14. Smoked cannabis reduces peak cocaine plasma levels and subjective effects in a controlled drug administration study of polysubstance use in men. Drug Alcohol Depend. 2023 02 01; 243:109757. Murray CH, Haney M, Foltin RW, Manubay J, Bedi G, Cooper ZD. PMID: 36608482; PMCID: PMC10058005.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    15. Understanding Cannabis Use Disorder Diagnoses in the U.S. Veterans Health Administration in the Era of Legalization. Am J Psychiatry. 2022 10; 179(10):702-704. Lake S, Cooper ZD. PMID: 36181332.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    16. Methadone Dose, Cannabis Use, and Treatment Retention: Findings From a Community-based Sample of People Who Use Unregulated Drugs. J Addict Med. 2023 Jan-Feb 01; 17(1):e18-e26. Lake S, Buxton J, Walsh Z, Cooper ZD, Socías ME, Fairbairn N, Hayashi K, Milloy MJ. PMID: 35914028; PMCID: PMC9889569.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    17. Cannabis and alcohol co-use: The effects of intensity of cannabis use among heavy drinkers. Addict Behav. 2022 Dec; 135:107443. Venegas A, Du H, Cooper ZD, Ray LA. PMID: 35932601.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    18. Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers. Addict Biol. 2022 07; 27(4):e13183. Haney M, Bedi G, Cooper ZD, Herrmann ES, Reed SC, Foltin RW, Kingsley PJ, Marnett LJ, Patel S. PMID: 35754107; PMCID: PMC9245164.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    19. Patterns of Use and Self-reported Effectiveness of Cannabis for Hyperemesis Gravidarum. Geburtshilfe Frauenheilkd. 2022 May; 82(5):517-527. First OK, MacGibbon KW, Cahill CM, Cooper ZD, Gelberg L, Cortessis VK, Mullin PM, Fejzo MS. PMID: 35528189; PMCID: PMC9076215.
      View in: PubMed   Mentions: 1     Fields:    
    20. Changes in secondary substance use after the onset of the COVID-19 pandemic among people who use cannabis: Findings from a web-based sample of adults in the United States. Exp Clin Psychopharmacol. 2023 Apr; 31(2):482-490. Lake S, Assaf RD, Gorbach PM, Cooper ZD. PMID: 35467920; PMCID: PMC9592680.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsPHPublic Health
    21. Drugs of Misuse: Focus on Vascular Dysfunction. Can J Cardiol. 2022 Sep; 38(9):1364-1377. Middlekauff HR, Cooper ZD, Strauss SB. PMID: 35462024; PMCID: PMC9474615.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    22. Changes in medical and non-medical cannabis use among United States adults before and during the COVID-19 pandemic. Am J Drug Alcohol Abuse. 2022 05 04; 48(3):321-327. Assaf RD, Gorbach PM, Cooper ZD. PMID: 35130464; PMCID: PMC9308664.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    23. Selective Changes in Medical Cannabis Use Early in the COVID-19 Pandemic: Findings from a Web-Based Sample of Adults in the United States. Cannabis Cannabinoid Res. 2023 02; 8(1):174-183. Lake S, Assaf RD, Gorbach PM, Cooper ZD. PMID: 35073161; PMCID: PMC9940798.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsPHPublic Health
    24. Challenges for Clinical Cannabis and Cannabinoid Research in the United States. J Natl Cancer Inst Monogr. 2021 11 28; 2021(58):114-122. Cooper ZD, Abrams DI, Gust S, Salicrup A, Throckmorton DC. PMID: 34850896; PMCID: PMC8783595.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    25. The Cannabis-Dependent Relationship Between Methadone Treatment Dose and Illicit Opioid Use in a Community-Based Cohort of People Who Use Drugs. Cannabis Cannabinoid Res. 2023 02; 8(1):155-165. Lake S, Kerr T, Buxton J, Walsh Z, Cooper ZD, Socías ME, Fairbairn N, Hayashi K, Milloy MJ. PMID: 34813374; PMCID: PMC9940808.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    26. Survey of Patients Employing Cannabigerol-Predominant Cannabis Preparations: Perceived Medical Effects, Adverse Events, and Withdrawal Symptoms. Cannabis Cannabinoid Res. 2022 10; 7(5):706-716. Russo EB, Cuttler C, Cooper ZD, Stueber A, Whiteley VL, Sexton M. PMID: 34569849; PMCID: PMC9587780.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    27. A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. Br J Clin Pharmacol. 2022 01; 88(1):347-355. Arout CA, Haney M, Herrmann ES, Bedi G, Cooper ZD. PMID: 34223660.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    28. A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness. Am J Drug Alcohol Abuse. 2021 09 03; 47(5):535-547. Kozak K, H Smith P, Lowe DJE, Weinberger AH, Cooper ZD, Rabin RA, George TP. PMID: 34280058; PMCID: PMC9144491.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    29. Self-administration of inhaled delta-9-tetrahydrocannabinol and synthetic cannabinoids in non-human primates. Exp Clin Psychopharmacol. 2021 Apr; 29(2):137-146. Cooper ZD, Evans SM, Foltin RW. PMID: 34043398; PMCID: PMC8376089.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    30. Motivational interviewing to treat substance use disorders in the emergency department: A scoping review. Am J Emerg Med. 2022 01; 51:414-417. Siegel R, Sullivan N, Monte AA, Vargas NM, Cooper ZD, Ma Y, Meltzer AC. PMID: 33840549.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    31. 5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers. Addict Biol. 2021 07; 26(4):e12993. Arout CA, Cooper ZD, Reed SC, Foltin RW, Comer SD, Levin FR, Haney M. PMID: 33389797; PMCID: PMC8225547.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    32. Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. Int J Clin Pract. 2021 Aug; 75(8):e13871. Sihota A, Smith BK, Ahmed SA, Bell A, Blain A, Clarke H, Cooper ZD, Cyr C, Daeninck P, Deshpande A, Ethans K, Flusk D, Le Foll B, Milloy MJ, Moulin DE, Naidoo V, Ong M, Perez J, Rod K, Sealey R, Sulak D, Walsh Z, O'Connell C. PMID: 33249713; PMCID: PMC8365704.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    33. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. Pharmacol Biochem Behav. 2020 12; 199:173059. Sholler DJ, Huestis MA, Amendolara B, Vandrey R, Cooper ZD. PMID: 33086126; PMCID: PMC7725960.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    34. Sex-dependent effects of alcohol administration on the urge to use cannabis. Exp Clin Psychopharmacol. 2021 Dec; 29(6):689-695. Venegas A, Meredith LR, Green R, Cooper ZD, Ray LA. PMID: 32658530; PMCID: PMC8409139.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimals
    35. Inclusion of Cannabis Users in Alcohol Research Samples: Screening In, Screening Out, and Implications. Alcohol Alcohol. 2020 Jun 25; 55(4):416-423. Venegas A, Meredith LR, Cooper ZD, Towns B, Ray LA. PMID: 32328657; PMCID: PMC7307319.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    36. Frequency of cannabis and illicit opioid use among people who use drugs and report chronic pain: A longitudinal analysis. PLoS Med. 2019 11; 16(11):e1002967. Lake S, Walsh Z, Kerr T, Cooper ZD, Buxton J, Wood E, Ware MA, Milloy MJ. PMID: 31743343; PMCID: PMC6863529.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimals
    37. Considering abuse liability and neurocognitive effects of cannabis and cannabis-derived products when assessing analgesic efficacy: a comprehensive review of randomized-controlled studies. Am J Drug Alcohol Abuse. 2019; 45(6):580-595. Cooper ZD, Abrams DI. PMID: 31687845; PMCID: PMC7279709.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    38. Cognitive function in aging cocaine smokers. J Psychopharmacol. 2019 07; 33(7):801-810. Chao T, Haney M, Cooper ZD, Vadhan NP, Van Dam NT, Van Snellenberg J, Bedi G. PMID: 31169441.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    39. Necessity of addressing motivations for cannabis use to guide research. Am J Drug Alcohol Abuse. 2019; 45(6):547-550. Cooper ZD, Adinoff B. PMID: 31755836; PMCID: PMC7307379.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    40. Cannabis legalization: progress in harm reduction approaches for substance use and misuse. Am J Drug Alcohol Abuse. 2019; 45(6):707-712. Adinoff B, Cooper ZD. PMID: 31755837.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    41. Varenicline and nabilone in tobacco and cannabis co-users: effects on tobacco abstinence, withdrawal and a laboratory model of cannabis relapse. Addict Biol. 2019 07; 24(4):765-776. Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, Foltin RW, Haney M. PMID: 30378231; PMCID: PMC8167505.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    42. Social motivational processing and interpersonal function in aging cocaine smokers. Addict Biol. 2019 09; 24(5):1044-1055. Bedi G, Hao X, Van Dam NT, Cooper ZD, Rubin E, Vadhan NP, Marino L, Haney M. PMID: 30328665.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    43. Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers. Addict Biol. 2019 07; 24(4):707-716. Haney M, Cooper ZD, Bedi G, Herrmann E, Comer SD, Reed SC, Foltin RW, Levin FR. PMID: 29659126; PMCID: PMC6191371.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimals
    44. Cannabis and the Opioid Crisis. Cannabis Cannabinoid Res. 2018; 3(1):108-116. Piomelli D, Weiss S, Boyd G, Pacula RL, Cooper Z. PMID: 29789812; PMCID: PMC5931647.
      View in: PubMed   Mentions: 5     Fields:    
    45. Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability. Neuropsychopharmacology. 2018 09; 43(10):2046-2055. Cooper ZD, Bedi G, Ramesh D, Balter R, Comer SD, Haney M. PMID: 29463913; PMCID: PMC6098090.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    46. Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073. Neuropharmacology. 2018 05 15; 134(Pt A):92-100. Cooper ZD, Poklis JL, Liu F. PMID: 29146503; PMCID: PMC5951724.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    47. Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective. Neuropsychopharmacology. 2018 Jan; 43(1):34-51. Cooper ZD, Craft RM. PMID: 28811670; PMCID: PMC5719093.
      View in: PubMed   Mentions: 115     Fields:    Translation:HumansAnimals
    48. Effects of ibudilast on oxycodone-induced analgesia and subjective effects in opioid-dependent volunteers. Drug Alcohol Depend. 2017 09 01; 178:340-347. Cooper ZD, Johnson KW, Vosburg SK, Sullivan MA, Manubay J, Martinez D, Jones JD, Saccone PA, Comer SD. PMID: 28688296.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    49. A Guide to the National Academy of Science Report on Cannabis: An Exclusive Discussion with Panel Members. Cannabis Cannabinoid Res. 2017; 2(1):155-159. Piomelli D, Cooper Z, Abrams D, Grant I, Patel S. PMID: 28861515; PMCID: PMC5569624.
      View in: PubMed   Mentions: 2     Fields:    
    50. Sex-dependent effects of cannabis-induced analgesia. Drug Alcohol Depend. 2016 Oct 01; 167:112-20. Cooper ZD, Haney M. PMID: 27522535; PMCID: PMC5037015.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimals
    51. Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. Curr Psychiatry Rep. 2016 May; 18(5):52. Cooper ZD. PMID: 27074934; PMCID: PMC4923337.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    52. Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users. Psychopharmacology (Berl). 2016 07; 233(13):2469-78. Herrmann ES, Cooper ZD, Bedi G, Ramesh D, Reed SC, Comer SD, Foltin RW, Haney M. PMID: 27085870; PMCID: PMC5302052.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    53. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. Neuropsychopharmacology. 2016 07; 41(8):1974-82. Haney M, Malcolm RJ, Babalonis S, Nuzzo PA, Cooper ZD, Bedi G, Gray KM, McRae-Clark A, Lofwall MR, Sparenborg S, Walsh SL. PMID: 26708108; PMCID: PMC4908634.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    54. The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. Addict Biol. 2016 07; 21(4):895-903. Cooper ZD, Johnson KW, Pavlicova M, Glass A, Vosburg SK, Sullivan MA, Manubay JM, Martinez DM, Jones JD, Saccone PA, Comer SD. PMID: 25975386; PMCID: PMC4644513.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    55. Naltrexone Maintenance Decreases Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers. Neuropsychopharmacology. 2015 Oct; 40(11):2489-98. Haney M, Ramesh D, Glass A, Pavlicova M, Bedi G, Cooper ZD. PMID: 25881117; PMCID: PMC4569951.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimals
    56. Novel Pharmacologic Approaches to Treating Cannabis Use Disorder. Curr Addict Rep. 2014 Jun 01; 1(2):137-143. Balter RE, Cooper ZD, Haney M. PMID: 24955304; PMCID: PMC4061701.
      View in: PubMed   Mentions: 26  
    57. Investigation of sex-dependent effects of cannabis in daily cannabis smokers. Drug Alcohol Depend. 2014 Mar 01; 136:85-91. Cooper ZD, Haney M. PMID: 24440051; PMCID: PMC4518446.
      View in: PubMed   Mentions: 89     Fields:    Translation:Humans
    58. Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts. Behav Pharmacol. 2013 Sep; 24(5-6):504-16. Comer SD, Metz VE, Cooper ZD, Kowalczyk WJ, Jones JD, Sullivan MA, Manubay JM, Vosburg SK, Smith ME, Peyser D, Saccone PA. PMID: 23839029; PMCID: PMC4056333.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    59. Marijuana's dose-dependent effects in daily marijuana smokers. Exp Clin Psychopharmacol. 2013 Aug; 21(4):287-93. Ramesh D, Haney M, Cooper ZD. PMID: 23937597; PMCID: PMC4547548.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansAnimals
    60. Effects of acute oral naltrexone on the subjective and physiological effects of oral D-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology. 2013 Nov; 38(12):2427-38. Comer SD, Mogali S, Saccone PA, Askalsky P, Martinez D, Walker EA, Jones JD, Vosburg SK, Cooper ZD, Roux P, Sullivan MA, Manubay JM, Rubin E, Pines A, Berkower EL, Haney M, Foltin RW. PMID: 23736314; PMCID: PMC3799062.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    61. Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone. Pain. 2013 Aug; 154(8):1442-8. Roux P, Sullivan MA, Cohen J, Fugon L, Jones JD, Vosburg SK, Cooper ZD, Manubay JM, Mogali S, Comer SD. PMID: 23707283; PMCID: PMC3770461.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    62. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology. 2013 Sep; 38(10):1984-92. Cooper ZD, Comer SD, Haney M. PMID: 23609132; PMCID: PMC3746706.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    63. Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse. Neuropsychopharmacology. 2013 Jul; 38(8):1557-65. Haney M, Cooper ZD, Bedi G, Vosburg SK, Comer SD, Foltin RW. PMID: 23443718; PMCID: PMC3682150.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansPHPublic Health
    64. Effects of menstrual cycle phase on cocaine self-administration in rhesus macaques. Horm Behav. 2013 Jan; 63(1):105-13. Cooper ZD, Foltin RW, Evans SM. PMID: 23098805; PMCID: PMC3540131.
      View in: PubMed   Mentions: 12     Fields:    Translation:Animals
    65. Predictors of marijuana relapse in the human laboratory: robust impact of tobacco cigarette smoking status. Biol Psychiatry. 2013 Feb 01; 73(3):242-8. Haney M, Bedi G, Cooper ZD, Glass A, Vosburg SK, Comer SD, Foltin RW. PMID: 22939992; PMCID: PMC3522776.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    66. A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers. Addict Biol. 2013 Nov; 18(6):993-1002. Cooper ZD, Foltin RW, Hart CL, Vosburg SK, Comer SD, Haney M. PMID: 22741619; PMCID: PMC3465638.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansPHPublic Health
    67. Effects of repeated oxycodone administration on its analgesic and subjective effects in normal, healthy volunteers. Behav Pharmacol. 2012 Jun; 23(3):271-9. Cooper ZD, Sullivan MA, Vosburg SK, Manubay JM, Haney M, Foltin RW, Evans SM, Kowalczyk WJ, Saccone PA, Comer SD. PMID: 22495183; PMCID: PMC3341961.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    68. Impact of in-patient research participation on subsequent heroin use patterns: implications for ethics and public health. Addiction. 2012 Mar; 107(3):642-9. Roux P, Tindall C, Fugon L, Murray J, Vosburg SK, Saccone P, Sullivan MA, Manubay JM, Cooper ZD, Jones JD, Foltin RW, Comer SD. PMID: 21939462; PMCID: PMC3335397.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    69. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol. 2013 Sep; 18(5):872-81. Bedi G, Cooper ZD, Haney M. PMID: 22260337; PMCID: PMC3335956.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansPHPublic Health
    70. Glial modulators: a novel pharmacological approach to altering the behavioral effects of abused substances. Expert Opin Investig Drugs. 2012 Feb; 21(2):169-78. Cooper ZD, Jones JD, Comer SD. PMID: 22233449; PMCID: PMC3314383.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    71. Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers. Behav Pharmacol. 2011 Aug; 22(4):354-61. Gooch CM, Rakitin BC, Cooper ZD, Comer SD, Balsam PD. PMID: 21750426; PMCID: PMC3182820.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    72. Reinforcer-dependent enhancement of operant responding in opioid-withdrawn rats. Psychopharmacology (Berl). 2010 Oct; 212(3):369-78. Cooper ZD, Shi YG, Woods JH. PMID: 20686752; PMCID: PMC3001287.
      View in: PubMed   Mentions: 17     Fields:    Translation:Animals
    73. Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology (Berl). 2010 Aug; 211(2):233-44. Haney M, Hart CL, Vosburg SK, Comer SD, Reed SC, Cooper ZD, Foltin RW. PMID: 20521030; PMCID: PMC3323354.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansPHPublic Health
    74. Opioid antagonism enhances marijuana's effects in heavy marijuana smokers. Psychopharmacology (Berl). 2010 Aug; 211(2):141-8. Cooper ZD, Haney M. PMID: 20490465; PMCID: PMC2923559.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    75. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers. Addiction. 2010 Apr; 105(4):709-18. Comer SD, Sullivan MA, Vosburg SK, Manubay J, Amass L, Cooper ZD, Saccone P, Kleber HD. PMID: 20403021; PMCID: PMC3489277.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    76. Evaluation of potential sex differences in the subjective and analgesic effects of morphine in normal, healthy volunteers. Psychopharmacology (Berl). 2010 Jan; 208(1):45-55. Comer SD, Cooper ZD, Kowalczyk WJ, Sullivan MA, Evans SM, Bisaga AM, Vosburg SK. PMID: 19859698; PMCID: PMC3320722.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    77. Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats. Drug Alcohol Depend. 2010 Jan 15; 106(2-3):219-29. Wood SK, Narasimhan D, Cooper Z, Sunahara RK, Woods JH. PMID: 19800183; PMCID: PMC3349347.
      View in: PubMed   Mentions: 15     Fields:    Translation:Animals
    78. Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and blunts. Drug Alcohol Depend. 2009 Aug 01; 103(3):107-13. Cooper ZD, Haney M. PMID: 19443132; PMCID: PMC2776770.
      View in: PubMed   Mentions: 103     Fields:    Translation:Humans
    79. Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence. Int Rev Psychiatry. 2009 Apr; 21(2):104-12. Cooper ZD, Haney M. PMID: 19367504; PMCID: PMC2731700.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimals
    80. A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality. Ann Emerg Med. 2009 Sep; 54(3):409-20. Jutkiewicz EM, Baladi MG, Cooper ZD, Narasimhan D, Sunahara RK, Woods JH. PMID: 19013687; PMCID: PMC3357128.
      View in: PubMed   Mentions: 16     Fields:    Translation:AnimalsCells
    81. Morphine deprivation increases self-administration of the fast- and short-acting mu-opioid receptor agonist remifentanil in the rat. J Pharmacol Exp Ther. 2008 Sep; 326(3):920-9. Cooper ZD, Truong YN, Shi YG, Woods JH. PMID: 18515643; PMCID: PMC3328857.
      View in: PubMed   Mentions: 30     Fields:    Translation:Animals
    82. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor. Addict Biol. 2008 Jun; 13(2):188-95. Cooper ZD, Haney M. PMID: 18279497; PMCID: PMC2731704.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimals
    83. Cocaine esterase: interactions with cocaine and immune responses in mice. J Pharmacol Exp Ther. 2007 Feb; 320(2):926-33. Ko MC, Bowen LD, Narasimhan D, Berlin AA, Lukacs NW, Sunahara RK, Cooper ZD, Woods JH. PMID: 17114567.
      View in: PubMed   Mentions: 38     Fields:    Translation:Animals
    84. Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol Pharmacol. 2006 Dec; 70(6):1885-91. Cooper ZD, Narasimhan D, Sunahara RK, Mierzejewski P, Jutkiewicz EM, Larsen NA, Wilson IA, Landry DW, Woods JH. PMID: 16968810.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCells
    85. Paradoxical effects of chronic morphine treatment on the temperature and pituitary-adrenal responses to acute restraint stress: a chronic stress paradigm. J Neuroendocrinol. 2001 Oct; 13(10):862-74. Houshyar H, Cooper ZD, Woods JH. PMID: 11679055.
      View in: PubMed   Mentions: 15     Fields:    Translation:Animals
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Ziva's Networks
    Concepts (255)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (19)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California